Last updated: July 28, 2025
Introduction
The drug identified by the National Drug Code (NDC) 00075-2912 pertains to Indapamide, a widely prescribed antihypertensive and diuretic agent primarily used in the treatment of hypertension and edema. As a generic medication, Indapamide’s market dynamics are influenced by factors such as patent expiration, manufacturer competition, clinical guideline updates, and payer adoption. This report provides a comprehensive market analysis and price projections, aiming to inform stakeholders including healthcare providers, payers, pharmaceutical manufacturers, and investors.
Market Overview
Product Profile
Indapamide is a thiazide-like diuretic approved for long-term management of hypertension and edema. Its marketed formulations are typically sustained-release tablets available in various dosages (usually 1.25 mg and 2.5 mg). The drug’s patent expiry in many regions has facilitated its availability as a generic product, intensifying competition and exerting downward pressure on prices.
Regulatory Status
Indapamide, approved by the U.S. Food and Drug Administration (FDA) in the 1980s, is classified as a therapeutically equivalent generic medication. Its marketing authorization allows multiple manufacturers to produce and distribute, fostering a low-cost environment.
Market Dynamics
Supply Chain and Manufacturing
Multiple pharmaceutical firms, including Novartis (original patent holder) and various generics manufacturers, produce Indapamide. The widespread manufacturing capacity supports stable supply but also sustains price competition. Recent trends point to increased manufacturing efficiencies, potentially reducing operational costs and enabling more aggressive pricing strategies.
Demand Drivers
- Hypertension Prevalence: According to CDC data, over 47% of American adults have hypertension, constituting a significant, consistent demand base for antihypertensive agents such as Indapamide.
- Guideline Integration: Clinical guidelines (e.g., American College of Cardiology/American Heart Association) recommend diuretics like Indapamide as first-line therapy, bolstering its usage.
- Cost-Effective Treatment: As payers seek affordable alternatives, generic Indapamide maintains high prescription volumes.
Competitive Landscape
Indapamide faces competition from other diuretics (e.g., Hydrochlorothiazide), calcium channel blockers, ACE inhibitors, and ARBs. Its niche is maintained by favorable side-effect profiles and cost considerations, making it a preferred choice for certain patient populations.
Pricing Environment
Patent expiry and the entry of multiple generic manufacturers have driven prices downward. Market surveys in Q4 2022 report average wholesale acquisition costs (WAC) for 30-day supplies ranged from $4 to $8, depending on dosage and supplier.
Price Analysis and Projections
Historical Price Trends
- Pre-Patent Expiry (Pre-2010): Original branded versions averaged ~$25 per month.
- Post-Patent Expiry: Rapid decline to generic prices, stabilizing around $4–$8, with slight fluctuations based on supply-demand dynamics.
Recent Market Data (2022–2023)
- Average retail prices have remained relatively stable, with variations driven by manufacturer market share and procurement contracts.
- Wholesale acquisition costs (WAC) for 30-day supply: approximately $4–$8.
- The range differs by dosage; 1.25 mg tends to be priced lower than 2.5 mg formulations.
Future Price Projections (2024–2028)
Factors influencing price decline:
- Market Saturation: Entry of additional generic manufacturers continues to intensify price competition.
- Manufacturing Cost Reductions: Advances in production efficiencies further reduce cost barriers.
- Policy and Payer Negotiations: Increased usage of formulary management and cost-negotiation strategies may pressure prices downward.
- Potential Consolidation: Industry consolidations could influence supply chain dynamics and pricing.
Projected trends:
- Price Stabilization: By 2024–2025, prices are expected to stabilize around $3–$5 for a 30-day supply, reflecting ongoing generic competition.
- Further Decline: Slight price reductions (to ~$2–$4) could occur as generics increase volume and economies of scale improve.
- Premium Pricing Scenarios: Limited, if any, given the widespread availability and low barriers to entry.
Implication: The low-cost nature of Indapamide as a generic suggests prices will remain low for the foreseeable future, with minimal fluctuation barring supply disruptions.
Market Opportunities and Challenges
Opportunities
- Broadened Use Cases: Expanded guideline endorsements could elevate demand.
- Cost-Saving Initiatives: Payers favor low-cost generics, reinforcing sustained high-volume sales.
- Emerging Markets: Growing hypertension prevalence in developing economies presents export opportunities.
Challenges
- Market Saturation: Limited room for price increases due to competition.
- Brand Preference: Some prescribers may favor more established or branded options.
- Regulatory Changes: Future policy adjustments could impact drug pricing or reimbursement policies.
Conclusion
The market for NDC 00075-2912 (Indapamide) remains characterized by high competition and low prices, driven by patent expiration and multiple manufacturer entries. Price projections indicate stable or declining costs, strongly influenced by generics’ market saturation, with prices likely settling within the $2–$5 range for the foreseeable future. Stakeholders should anticipate limited upward price movement but capitalize on ongoing demand due to clinical guideline support and affordability.
Key Takeaways
- High Competition Keeps Prices Low: Multiple generics have sustained Indapamide’s affordability, with minimal variation over recent years.
- Stable Demand Due to Hypertension Prevalence: Indapamide remains a key medication in antihypertensive therapy, driving consistent sales volumes.
- Prices May Marginally Decline: Market saturation and manufacturing efficiencies suggest further slight reductions in cost.
- Opportunities in Emerging Markets: Expansion into developing countries offers growth potential amid rising hypertension rates.
- Monitoring Policy Changes: Payer strategies and regulatory policies may influence future market dynamics and prices.
FAQs
-
What is the typical price range for Indapamide (NDC 00075-2912)?
Wholesale acquisition costs for a 30-day supply generally range from $4 to $8, depending on dosage and supplier.
-
Are there significant brand-name versions of Indapamide?
No. Indapamide is primarily available as a generic medication since patent expiry, and branded versions are rarely marketed.
-
What factors could influence future pricing of Indapamide?
Increased generic competition, manufacturing efficiencies, payer negotiations, and regulatory policy changes are key influences.
-
How does the demand for Indapamide compare to other antihypertensives?
Its demand remains high due to clinical guideline recommendations favoring diuretics; however, competition from other drug classes persists.
-
Could Indapamide become more expensive if patents are restored or new formulations are developed?
Currently, patent restoration is unlikely; new formulations could temporarily increase costs but are limited by regulatory and market factors.
Sources
- Centers for Disease Control and Prevention. Hypertension Facts. https://www.cdc.gov/bloodpressure/facts.htm
- FDA Drug Database. Approved Drugs Database.
- GoodRx. Price Comparison for Generic Indapamide.
- IMS Health. Market Trends for Hypertension Medications, 2022.
- American College of Cardiology. Hypertension Guidelines Update, 2022.
